Transcranial Magnetic Stimulation in Substance Use Disorder Patients

Status Not yet recruiting

Clinical Trial Summary

To determine the effect of substance use disorder on cortical excitability using transcranial magnetic stimulation (TMS) , it's a scientific study

Clinical Trial Description

The numbers for substance use disorders are large, and we need to pay attention to them. Data from the 2018 National Survey on Drug Use and Health suggest that, over the preceding year, 20.3 million people age 12 or older had substance use disorders, and 14.8 million of these cases were attributed to alcohol. When considering other substances, the report estimated that 4.4 million individuals had a marijuana use disorder and that 2 million people suffered from an opiate use disorder. It is well known that stress is associated with an increase in the use of alcohol and other substances, and this is particularly relevant today in relation to the chronic uncertainty and distress associated with the COVID-19 pandemic along with the traumatic effects of racism and social injustice,Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull). Since its introduction in the mid-1980s is used to evaluate the cortico-spinal tract, cortical motor areas,, map motor and cognitive functions, study neural networks, and modulate brain function with a potential therapeutic aim, On one hand, the development of specific stimulation protocols, such as the cortical silent period (CSP) and paired-pulse paradigms, as well as the emerging concept that motor cortical output is affected by non-primary motor areas, including the ventral and dorsal premotor cortex, supplementary motor area, and cingulate cortex, has allowed the use of TMS to explore inhibitory and excitatory interactions within motor cortical regions in several neuropsychiatric disorders. Different TMS protocols can be used to study different components of cortical excitability and provide insight in to the regulation of different neurotransmitter systems. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06066164
Study type	Interventional
Source	Assiut University
Contact	Abdelrahman H Goda
Phone	01061236939
Email	Abdelrahmangoda17@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	December 2023
Completion date	October 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05660434` - Using Aromatherapy in Substance Use Disorder	N/A
Recruiting	`NCT05338268` - Substance Use and Loneliness	N/A
Completed	`NCT04098614` - Barriers to Substance Use Disorder Recovery	N/A
Completed	`NCT03954184` - E-health Implementation (Iowa)	N/A
Completed	`NCT03590106` - Cardiac Surgery Peer Recovery Support Program	N/A
Recruiting	`NCT05118204` - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization	Phase 4
Recruiting	`NCT06273228` - Parenting Young Children in Pediatrics	N/A
Recruiting	`NCT05327504` - Written Exposure Therapy for Veterans With SUD and PTSD	N/A
Terminated	`NCT03517111` - The Impact of a Parenting Intervention on Latino Youth Health Behaviors	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Completed	`NCT04401215` - Technologically-Augmented Referrals to Mitigate Addiction Consequences	N/A
Not yet recruiting	`NCT06163651` - Evaluating a One-Year Version of the Parent-Child Assistance Program	N/A
Not yet recruiting	`NCT06187701` - Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients	N/A
Recruiting	`NCT04296604` - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations	N/A
Active, not recruiting	`NCT02382042` - Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans	N/A
Completed	`NCT01237366` - Study Targeting Affect Regulation	Phase 1/Phase 2
Terminated	`NCT01356667` - Drum-Assisted Therapy for Native Americans	N/A
Completed	`NCT00708890` - Twelve Step Based Self-help Groups for Substance Related Disorders	N/A
Active, not recruiting	`NCT04048850` - Zepatier in Patients With Substance Use
Recruiting	`NCT05976646` - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.